Page 12 - VB

KNOWING EARLIER TO GIVE THEM A LATER® EARLY FRONTLINE IDENTIFICATION — enabling earlier intervention
when outcomes are likely to be better
ACCURATE — the only product line that detects the tumor-initiating and stem cell-associated biomarker CD44 and total protein
NON-INVASIVE — in-office collection of oral rinse sample for the OncAlert Oral Cancer RAPID Test and the OncAlert Oral Cancer LAB Test
COST-EFFECTIVE — applicable for a broad range of patients FAST — easy-to-interpret results in 10 minutes with OncAlert
Oral Cancer RAPID Test
Give patients a better later, with the OncAlert Oral Cancer product line.
Order today through your local OncAlert Oral Cancer distributor or at www.oncalert.com
Sources:
1 WHO 2014-2015 World Cancer Report
2 Pereira LH, Reis IM, Reategui EP, Gordon C, Saint-Victor S, Duncan R, Gomez C, Bayers S, Fisher P, Perez A, Goodwin WJ, Hu JJ, Franzmann EJ. Risk Stratification System for Oral Cancer Screening. Cancer Prev Res (Phila). 2016 Jun;9(6):445-55.
References:
Head and Neck Cancer, Union for International Cancer Control. 2014 Review of Cancer Medicine on the WHO List of Essential Medicines. World Health Organization website. http://www.who.int/selection_ medicines/committees/expert/20/applications/HeadNeck.pdf?ua=1. Accessed June 25, 2015.
Oral cancer facts. Oral Cancer Foundation website. http://www.oralcancerfoundation.org/facts/. Accessed June 25, 2015.
Mateus Pereria LH, Reis IM, Reategui EP et al. Risk stratification system for oral cancer screening [published online ahead of print March 28, 2016]. Cancer Prev Res (Phila). 2016. doi: 10.1158/1940-6207.CAPR-15-0200.
Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65(2):87-108.
Mehanna H, Beech T, Nicholson T, et al. Prevalence of human papillomavirus in oropharyngeal and nonoropharyngeal head and neck cancer—systematic review and meta analysis of trends by time and region. Head Neck. 2013;35(5):747-755.
Why screening works. Oral Cancer Foundation website. http://oralcancerfoundation.org/dental/why_screening_works.php. Accessed June 25, 2015.
Petersen PE. Strengthening the prevention of oral cancer: the WHO perspective. Community Dent Oral Epidemiol. 2005;33(6):397-399.
Head and neck cancers. National Cancer Institute website. http://www.cancer.gov/types/head-and-neck/head-neck-fact-sheet#q1. Accessed June 26, 2015.
Franzmann E, Cowden S, Kim M, Ginn G, Bohannon R. Oral Rinse Test as a Diagnostic aid for oral cancer. J Clin Oncol. 2016; 34 (suppl; abstr e17509)
Franzmann EJ, Reategui EP, Pedrosos F, et al. Soluble CD44 is a potential marker for the early detection of head and neck cancer. Cancer Epidemiol Biomarkers Prev. 2007;16(7):1348-1355.
Sankaranarayanan R, Ramadas K, Thomas G, et al. Effect of screening on oral cancer mortality in Kerala, India: a cluster-randomised controlled trial. Lancet. 2005;363(9475):1927-1933.
Sankaranarayanan R, Mathew B, Jacob BJ, et al. Early findings from a community-based, cluster randomized, controlled oral cancer screening trial in Kerala, India. Cancer. 2000;88(3):664-673.
Su WW, Yen AM, Chiu SY, Chen TH. A community-based RCT for oral cancer screening with toluidine blue. J Dent Res. 2010;89(9):933-937.
Mehrotra R, Singh M, Thomas S, et al. A cross-sectional study evaluating chemiluminescence and autofluorescence in the detection of clinically innocuous precancerous and cancerous oral lesions. J Am Dent Assoc. 2010;141(2):151-156.
Hohlweg-Majert B, Deppe H, Metzger MC, et al. Sensitivity and specificity of oral brush biopsy. Cancer Invest. 2009;27(3):293-297.
Elashoff D, Zhou H, Reiss J, et al. Prevalidation of salivary biomarkers for oral cancer detection. Cancer Epidemiol Biomarkers Prev. 2012;21(4):664-672.
Carvalho AL, Jeronimo C, Kim MM, et al. Evaluation of promoter hypomethylation detection in body fluids as a screening diagnosis tool for head and neck squamous cell carcinoma. Clin Cancer Res. 2008;14(1):97-107.
Neville BW, Day TA. Oral cancer and precancerous lesions. CA Cancer J Clin. 2002;52:195-215.
6301 NW 5th Way | Suite 1500 Ft. Lauderdale, FL 33309 info@vigilantbiosciences.com
Copyright 2018 by or under the license of Vigilant Biosciences, Inc. All rights reserved. Subject to issued and pending international patent protection. All marks used herein are owned by Vigilant Biosciences, Inc.
BR00-0001-revE